Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 10, 2025-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

• TD Cowen Immunology and Inflammation Virtual Summit
  Date: Wednesday, November 12, 2025
  Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT

• Piper Sandler 37th Annual Healthcare Conference
  Date: Tuesday, December 2, 2025
  Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at https://www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit https://www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110946225/en/

Charles Liles [email protected] (626) 737-8118

Source: Xencor, Inc.